Precision Medicine in Central Nervous System Drug Development
Precision medicine aims to target the right treatments to the right patients at the right time.
Discover the latest innovations in precision medicine to treat disorders of the central nervous system.
In this webinar you’ll learn:
What lessons can we learn from the use of precision medicine in oncology?
How has a recent clinical precision medicine application shown potential in the treatment of Alzheimer’s?
What questions should you ask before you add a new biomarker to your clinical trial?
What are the pros and cons of using biomarkers as surrogate endpoints?
Daniel Klamer, MS, Ph.D., MBA
VP, Business Development & Scientific Strategy
Anavex Life Sciences Corporation
Dr. Daniel Klamer, has more than 15 years of experience in neuroscience and the orphan disease space, with acquisition, partnering and R&D experience in Europe and the U.S. Prior to Anavex, he worked at Retrophin and Neurosearch Sweden. At Neurosearch Sweden, Dr. Klamer led and evaluated multiple discovery-phase neuropharmacological research products with an emphasis on strategic evaluation of preclinical and clinical development.
Dr. Klamer earned his Ph.D. in Pharmacology at The Sahlgrenska Academy at the University of Gothenburg, Sweden, his MBA at Fordham Gabelli School of Business, and his Post-Doctoral training at the Department of Psychiatry, Yale University School of Medicine. In addition, Dr. Klamer holds a position as an Associate Professor at the Department of Pharmacology at The Sahlgrenska Academy at the University of Gothenburg. Learn more.